Find information on thousands of medical conditions and prescription drugs.

Dactinomycin

Actinomycin is any of a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It was the first antibiotic shown to have anti-cancer activity, but is not normally used as such, as it is highly toxic, causing damage to genetic material. It is mainly used as an investigative tool in cell biology.

Actinomycin-D is marketed under the trade name Dactinomycin. It binds to DNA duplexes, thereby interfering with the action of enzymes engaged in replication and transcription. Actinomycin-D is one of the older chemotherapy drugs which has been used in therapy for many years. It is a clear, yellow liquid which is administered intravenously and most commonly used in treatment of a variety of cancers.

Read more at Wikipedia.org


[List your site here Free!]


Update on childhood rhabdomyosarcoma - Tips - Author Abstract
From American Family Physician, 7/15/03 by Anne D. Walling

Approximately 7 percent of childhood malignancies are soft tissue sarcomas. One half of these malignancies are rhabdomyosarcomas (RMS) originating in striated muscle. Although adult sarcomas primarily involve the extremities, RMS in children can occur in any anatomic location, including locations with no skeletal muscle. The most common sites are in the genitourinary systems, extremities, head, and neck. A review by Andrassy emphasizes the importance of tumor location and individualized management in the prognosis of RMS in children.

The clinical presentation depends on tumor location and size. About one third of cases originate in the head and neck, and 25 to 35 percent of these have central nervous system involvement. The presentation may be of an unexplained mass or cranial nerve palsies, meningeal symptoms, or even respiratory problems caused by brainstem infiltration. About 26 percent of pediatric RMS cases occur in the genitourinary system. The painless swelling may initially be diagnosed as a hernia, hydrocele, or varicocele in boys and may cause bleeding, vaginal discharge, or a mass in girls. In adolescents, RMS more commonly presents as a painless mass in the extremities, but up to one half of cases have spread to lymph nodes by the time of diagnostic biopsy. Regardless of site, biopsy is key to diagnosis and staging. Excisional biopsy is possible in some cases, depending on the location and size of the lesion. Even with clear margins, regional node sampling is recommended following wide excisional biopsy to plan radiation therapy or other subsequent treatment and more accurately provide prognosis. Depending on the situation, computed tomography or magnetic resonance imaging assessment of the primary site, regional nodes, or areas of likely metastasis also may be indicated for diagnosis and staging. The Intergroup RMS Study system of staging correlates with overall survival (see the accompanying table). Five-year survival for patients in group I is more than 90 percent following complete excision, whereas rates for patients in group IV average 30 to 35 percent.

Complete local excision is the recommended initial treatment of RMS, except for lesions of the orbit, vagina, or bladder. In these locations, chemotherapy, with or without radiation, plus limited surgery, provides results comparable with more aggressive surgery. Regardless of site or type of tumor, surgery must be carefully planned to balance the need for tumor removal against loss of function and mutilation. Overall, surgical treatment has become less aggressive, with more patients being managed by limited initial surgery followed by chemotherapy or subsequent surgeries. The traditional mainstay of chemotherapy for RMS has been combinations of vincristine, dactinomycin, and cyclophosphamide. Other drugs such as doxorubicin, ifosphamide, actinomycin, topotecan, and irinotecan may be used as part of combination therapy targeting specific tumor types. Radiation (usually external beam) is used selectively to enhance local tumor control.

The management of RMS depends on the site and type of tumor. Surgery is often limited in the head and neck for cosmetic reasons and because metastasis to cervical nodes is rare. Biopsy plus chemotherapy and radiation can result in 90 percent survival rates in orbital lesions without the need for extensive surgery. In RMS of the bladder, more conservative surgical treatments have resulted in 85 percent survival, with 60 percent of patients retaining bladder function. The treatment of paratesticular RMS is controversial because of the high probability of retroperitoneal lymph node involvement, especially in adolescents. Radical inguinal orchiectomy is recommended, but experts disagree on the extent of retroperitoneal node dissection. Adjuvant chemotherapy combined with surgery results in survivals of more than 90 percent. For lesions of the female genital tract, management is now based on local resection followed by chemotherapy with or without selective radiotherapy. Radical surgical excision is no longer recommended. The worst outlook in RMS is in patients with lesions in the extremities. Surgery must balance limb sparing and good functional outcome with eradication of disease. Up to one half of patients with RMS of the extremities have positive lymph nodes and require radiation therapy.

Andrassy RJ. Advances in the surgical management of sarcomas in children. Am J Surg December 2002;184:484-91.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group

Return to Dactinomycin
Home Contact Resources Exchange Links ebay